Processing of the NF-κB2 precursor p100 to p52 is critical for RANKL-induced osteoclast differentiation

Journal of Bone and Mineral Research

Volumn 25, Issue 5, 2010, Pages 1058-1067

  Maruyama, Toshimasa ^a   Fukushima, Hidefumi ^a   Nakao, Kayoko ^a   Shin, Masashi ^a   Yasuda, Hisataka ^b   Weih, Falk ^c   Doi, Takahiro ^d   Aoki, Kazuhiro ^e   Alles, Neil ^e   Ohya, Keiichi ^e   Hosokawa, Ryuji ^a   Jimi, Eijiro ^a  

^a KYUSHU DENTAL COLLEGE   (Japan)

^b Oriental Yeast Co Ltd   (Japan)

^c FRITZ LIPMANN INSTITUTE   (Germany)

^d RIKEN BIORESOURCE CENTER   (Japan)

^e TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Alternative NF B pathway; Alymphoplasia (aly aly) mice; NIK; Osteoclastogenesis; Osteopetrosis

Indexed keywords

I KAPPA B ALPHA; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN P100; PROTEIN P52; TRANSCRIPTION FACTOR NFAT;

ALBERS SCHOENBERG DISEASE; ANIMAL CELL; ARTICLE; BONE MARROW CELL; CELL COUNT; CELL DIFFERENTIATION; CORRELATION ANALYSIS; FEMALE; GENE MUTATION; GENETIC TRANSFECTION; MALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; WILD TYPE;

ANIMALS; CELL DIFFERENTIATION; FEMALE; I-KAPPA B KINASE; MALE; MICE; MICE, KNOCKOUT; NF-KAPPA B; NF-KAPPA B P52 SUBUNIT; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; PROTEIN-SERINE-THREONINE KINASES; RANK LIGAND;

EID: 77953482256     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.091032     Document Type: Article

References (36)

1. Chambers TJ, Thomson BM, Fuller K. Effect of substrate composition on bone resorption by rabbit osteoclasts. J Cell Sci. 1984;70:61-71. (Pubitemid 15220225)
2. Baron R, Neff L, Louvard D, Courtoy PJ. Cell-mediated extracellular acidification and bone resorption: evidence for a low pH in resorbing lacunae and localization of a 100-kDa lysosomal membrane protein at the osteoclast ruffled border. J Cell Biol. 1985;101:2210-2222. (Pubitemid 16169951)
3. Suda T, Takahashi N, Martin TJ. Modulation of osteoclast differentiation. Endocr Rev. 1992;13:66-80.
4. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev. 1999;20:345-357. (Pubitemid 30649812)
5. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423:337-342.
6. Nakashima T, Wada T, Penninger JM. RANKL and RANK as novel therapeutic targets for arthritis. Curr Opin Rheumatol. 2003;15:280-287. (Pubitemid 36532608)
7. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397:315-323. (Pubitemid 129638144)
8. Dougall WC, Glaccum M, Charrier K, et al. RANK is essential for osteoclast and lymph node development. Genes Dev. 1999;13: 2412-2424. (Pubitemid 29453612)
9. Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997;390:175-179. (Pubitemid 27507987)
10. Jimi E, Akiyama S, Tsurukai T, et al. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function, J. Immunol. 1999;163:434-442. (Pubitemid 29295871)
11. Iotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R. Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nat Med. 1997;3:1285-1289.
12. Franzoso G, Carlson L, Xing L, et al. Requirement for NF-κB in osteoclast and B-cell development. Genes Dev. 1997;11:3482-3496.
13. Bonizzi G, Karin M. The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 2004;25: 280-288.
14. Ghosh S, Karin M. Missing pieces in the NF-κB puzzle. Cell. 2002;109 Suppl: S81-96.
15. Ghosh S, Hayden MS. New regulators of NF-κB in inflammation. Nat Rev Immunol. 2008;8:837-848.
16. Xiao G, Harhaj EW, Sun SC. NF-κB-inducing kinase regulates the processing of NF-κB2 p100. Mol Cell. 2001;7:401-409.
17. Jimi E, Aoki K, Saito H, et al. Selective inhibition of NF-κB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med. 2004;10:617-624.
18. Dai S, Hirayama T, Abbas S, Abu-Amer Y. The IκB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. J Biol Chem. 2004;279:37219-37222.
19. Ruocco MG, Maeda S, Park JM, et al. IKKβ, but not IKKα, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med. 2005;201:1677-1687.
20. Novack DV, Yin L, Hagen-Stapleton A, et al. The IκB function of NF-κB2 p100 controls stimulated osteoclastogenesis. J Exp Med. 2003;198:771-781.
21. Vaira S, Johnson R, Hirbe AC, et al. Rel B is the NF-κB subunit downstream of NIK responsible for osteoclast differentiation. Proc Natl Sci USA. 2008;105:3897-3902.
22. Shinkura R, Kitada K, Matsuda F, et al. Alymphoplasia is caused by a point mutation in the mouse gene encoding NF-κB-inducing kinase. Nat Genet. 1999;22:74-77. (Pubitemid 29214808)
23. Macpherson AJ, Uhr T. The donor splice site mutation in NF-κB-inducing kinase of alymphoplasia (aly/aly) mice. Immunogenetics. 2003;54:693-698. (Pubitemid 36188534)
24. Aoki K, Saito H, Itzstein C, et al. A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss. J Clin Invest. 2006;116:1525-1534. (Pubitemid 43911007)
25. Fukushima H, Nakao A, Okamoto F, et al. The association of Notch2 and NF-κB accelerates RANKL-induced osteoclastogenesis. Mol Cell Biol. 2008;28:6402-6412.
26. Kitamura T, Koshino Y, Shibata F, et al. Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics. Exp Hematol. 2003;31:1007-1014. (Pubitemid 37329742)
27. Nosaka T, Kawashima T, Misawa K, Ikuta K, Mui AL, Kitamura T. STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells. EMBO J. 1999;18:4754-4765. (Pubitemid 29415529)
28. Heusch M, Lin L, Geleziunas R, Greene WC. The generation of nfkb2 p52: mechanism and efficiency. Oncogene. 1999;18:6201-6208.
29. Malinin NL, Boldin MP, Kovalenko AV, Wallach D. MAP3K-related kinase involved in NF-κB induction by TNF, CD95 and IL-1. Nature. 1997;385:540-544.
30. Rangaswami H, Bulbule A, Kundu GC. Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IκBα kinase-dependent nuclear factor κB-mediated promatrix metalloproteinase-9 activation. J Biol. Chem. 2004;279:38921-38935. (Pubitemid 39296053)
31. Takayanagi H, Kim S, Matsuo K, et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-γ. Nature. 2002;416:744-749. (Pubitemid 34429151)
32. Takayanagi H, Kim S, Koga T, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. 2002;3:889-901. (Pubitemid 35460788)
33. Régnier CH, Song HY, Gao X, Goeddel DV, Cao Z, Rothe M. Identification and characterization of an IkB kinase. Cell. 1997;90:373-383.
34. Fusco AJ, Savinova OV, Talwar R, Kearns JD, Hoffmann A, Ghosh G. Stabilization of Rel B requires multidomain interactions with p100/ p52. J Biol Chem. 2008;283:12324-12332.
35. Tucker E, O'Donnell K, Fuchsberger M, et al. A novel mutation in the Nfkb2 gene generates an NF-κB2 "super repressor." J Immunol. 2007;179:7514-7522.
36. Ramakrishnan P, Wang W, Wallach D. Receptor-specific signaling for both the alternative and the canonical NF-κB activation pathways by NF-κB-inducing kinase. Immunity. 2004;21:477-489. (Pubitemid 39370504)